Wednesday, March 26, 2025

Fw: Ref.: (LML) LRI Spring Meeting 2025

 

 

Leprosy Mailing List –  March 26,  2025

 

Ref.:  (LML)  LRI Spring Meeting 2025

From:  LRI, Amsterdam, the Netherlands

 

 

 

Dear colleagues,

 

Join us for the LRI Spring Meeting 2025!

 
The Leprosy Research Initiative (LRI) Spring Meeting is back for its tenth edition, bringing together researchers, experts, and professionals to share the latest advancements in leprosy research. This key event serves as a vital platform for knowledge exchange, discussion, and connecting with colleagues worldwide.
 
What to expect?

✔ Inspiring keynote presentations from leading experts.

✔ Project presentations showcasing the progress of 33 LRI-funded research projects.
✔ Opportunities for Q&A and interacting with researchers and peers from around the globe.
 

Why attend?

✔ Stay updated on the latest research and findings in the leprosy field.
✔ Connect with international colleagues and exchange insights.

✔ Participate for free—no cost to attend!
 
🔗 Register & explore the programme!

Secure your spot today by visiting our event website. Don't miss this opportunity to be part of an essential conversation in leprosy research.

 

 

 

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/c932fd05-53ad-4e84-97b5-ae4208d04f53n%40googlegroups.com.
Posted by at No comments:

Tuesday, March 25, 2025

Fw: Ref.: (LML) Kindness as a key ingredient of HD control

 

Leprosy Mailing List –  March 25,  2025

 

Ref.:  (LML)  Kindness as a key ingredient of HD control

From: Joel Almeida, Mumbai, India

 

 

 

Dear Pieter and colleagues,

It turns out that household incomes in Maranhão, Brazil, increased dramatically from 2022 onwards. This was accompanied by reported declines in the annual rate of newly detected LL (lepromatous) HD (leprosy) with G2D (visible deformity at diagnosis). (Ministry of Health, Brazil) Programs such as Bolsa Familia and Fome Zero in Brazil tend to decrease nutritional deficiencies. Otherwise Vit D deficiency can reduce the likelihood of safe self-healing .

There are many ingredients of effective HD control and care. Kindness is usually not mentioned in guidelines. However, most people value kindness, especially if it is shown towards themselves. In the case of exemplars such as Jozef Damien de Veuster, kindness is deeply valued by many because it was shown towards others (persons who experience(d) HD). 

Brazil is not alone in respecting people at the bottom of the heap. Several endemic countries do so. What happens when kindness and respect become drivers of public policy?  Maranhão offers some clues. 

 

People in  Maranhão do not necessarily have the best training in Brazil. They do not necessarily have the  most advanced technology. They certainly do not have the highest incomes. All that needs to keep improving. Despite the room for improvement, they managed to decrease the reported new case detection rate of LL HD with G2D steadily during 2021 to 2023. That suggests steadily fewer LL HD patients had delayed diagnosis. This implies a steady reduction in an important source of astronomical numbers of viable bacilli, given the importance of the nasal mucosa in LL HD. (1) Also, the reported percentage of newly diagnosed HD patients with G2D decreased between 2023 and 2024, suggesting more intensive case-finding in 2024. 

 

Despite all the more intensive case-finding in 2024 than in 2023, 17% fewer HD cases (all classifications) were found in 2024 compared to 2023, and 28% fewer child HD cases. Even though these figures might be updated, this could turn out to be the start of a beneficial trend. That is because new LL HD with G2D is one of the most important predictors of the subsequent incidence rate of HD. 

Maranhão, despite its promising outcomes, still shows an increase in recurrent HD. This is a threat. Genomically susceptible LL HD persons who were previously treated can again become a major source of viable bacilli. Once recurrence and reinfection are reduced to negligible levels by kinder and more enlightened case management policies, there is every chance that the 2021-2023 decrease of LL HD G2D in Maranhão will ripen into a relentless decline in the incidence rate of all HD. Such sustained achievement, not inconceivable, could match the rapid decline of HD achieved in Malta, Weifang/Shandong (China), Karigiri (India), Pakistan, Thailand, Vietnam, Ecuador etc. HD and its deforming sequelae are an important cause of destitution. The sustained decline of HD in low-income states such as Maranhão therefore would be particularly beneficial. Maranhão shows what is possible despite all the known disadvantages. 

Brazilian science is a world leader in HD. It is fitting that kindness in public policy, alongside this scientific leadership, is producing world-leading declines in the endemicity of HD. How can Maranhão further improve its clinical and epidemiological impact? According to the data, the typical person with newly diagnosed LL HD and G2D (visible deformity) in Maranhão is an adult male with no more than 4 years of schooling,. Men with little or no schooling probably deserve the most focus. Fortunately, in untreated LL HD bacilloscopy of skin smears or nasal smears tends to show astronomical numbers of bacilli. That permits prompt diagnosis especially in high-endemic neighbourhoods or workplaces. These bacilli are the main driver of the endemic. Finding these persons before they develop visible deformity and ensuring good treatment and respectful case management is not only kind to them, but also can switch off a major source of concentrated viable bacilli. 


A brief burst of anti-microbials is far from kind. The opportunity for safe self-healing is removed. That is because anti-microbials can activate surviving dormant bacilli in perineural macrophages, release TR9 ligands leading to a cytokines storm, remove the helpful anti-apoptotic effect of live M. leprae, reduce the helpful secretion of insulin-like growth factor-1 by macrophages, switch off the diversion by live M. leprae of host citrate to lipid synthesis within macrophages which otherwise helpfully reduces host mitochondrial membrane potential and damaging reactive oxygen species etc. (2-9) Most of this important knowledge comes from world-leading Brazilian research. Only a full course of anti-microbials with regular nerve function monitoring and good case management can adequately protect the recipient's nerves, limbs and eyes once the opportunity for safe self-healing is removed by giving a dose of anti-microbials to an infected contact. Fortunately Brazil has independent policies that are both scientifically enlightened and kind.


Without kindness, everything can fall apart. Even the Universal Declaration of Human Rights (UDHR) at its heart is based on respect and kindness: "Whereas disregard and contempt for human rights have resulted in barbarous acts which have outraged the conscience of mankind ...". (from preamble to UDHR) Wherever human rights are disregarded, needless suffering can be inflicted on persons who experience(d) HD and their family members. That was not the approach of Jozef Damien de Veuster, and it need not be our approach. 


At the level of the individual patient and individual health worker we have many heroes and heroines who demonstrate kindness. May their number grow. 

With all sincerity,

Joel Almeida

 

 

REFERENCES

1.      Davey TF, Rees RJ. The nasal dicharge in leprosy: clinical and bacteriological aspects. Lepr Rev. 1974 Jun;45(2):121-34.

 

2.     Medeiros RCA, Girardi KdCdV, Cardoso FKL et al. Subversion of Schwann Cell Glucose Metabolism by Mycobacterium leprae. J Biol Chem. 2016 Aug 23;291(41):21375–21387. doi:10.1074/jbc.M116.725283

3.      Rodrigues LS, da Silva Maeda E, Moreira ME et al. Mycobacterium leprae induces insulin-like growth factor and promotes survival of Schwann cells upon serum withdrawal. Cell.Microbiol. (2010) 12: 42–54

4.      Souza BJd, Mendes MA, Sperandio da Silva GM et al. Gene Expression Profile of Mycobacterium leprae Contribution in the Pathology of Leprosy Neuropathy. Front. Med. (2022) 9:861586. doi: 10.3389/fmed.2022.861586

5.      Salgado CG, Pinto P, Bouth RC, Gobbo AR, Messias ACC, Sandoval TV et al. miRNome Expression Analysis Reveals New Players on Leprosy Immune Physiopathology. Front Immunol. (2018) 9:463. doi: 10.3389/fimmu.2018.00463. PMID: 29593724; PMCID: PMC5854644.

6.     Machado D, Lecorche E, Mougari F et al. Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence. Front. Microbiol. (2018) 9:3072. doi: 10.3389/fmicb.2018.03072

 

7.      Madigan CA, Cambier CJ, Kelly-Scumpia et al. A Macrophage Response to Mycobacterium leprae Phenolic Glycolipid Initiates Nerve Damage in Leprosy. Cell (2017) 170(5):973-985. e10. doi: 10.1016/j.cell.2017.07.030.

8.     Dias AA, Silva CO, Santos JPS, Batista-Silva LR, Acosta CCD, Fontes ANB, et al. DNA sensing via TLR-9 constitutes a major innate immunity pathway activated during erythema nodosum leprosum. J Immunol (2016) 197:1905–13. 10.4049/jimmunol.1600042

 

9.     Brugger LMdO, Monnerat M, dos Santos L, Lara FA, Mietto BS. What happens when Schwann cells are exposed to Mycobacterium leprae - A systematic review. IBRO Neuroscience Reports. (2023) 15:11-16

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/d76d3ac4-6d1f-4bb7-a0b0-b017955c8801n%40googlegroups.com.
Posted by at No comments:

Fw: Ref.: (LML) WHO Goodwill Ambassador's Leprosy Bulletin NO. 125, March 2025

 

 

Leprosy Mailing List –  March 25,  2025

 

Ref.:  (LML) WHO Goodwill Ambassador's Leprosy Bulletin NO. 125, March 2025

From: Takahiro NANRI, Tokyo, Japan

 

 

Dear Dr. Schreuder and Friends,  

 

 

Warm greetings from Sasakawa Health Foundation/ Sasakawa Leprosy (Hansen's Disease) Initiative in Tokyo.

 

We have issued WHO Goodwill Ambassador's Leprosy Bulletin NO.125 March 2025 "Breaking barriers to healthcare for persons affected by leprosy." In this issue, we feature: 

 

MESSAGE FROM THE AMBASSADOR
On Jan. 30, the date that India observes its national version of World Leprosy Day, the "Global Appeal 2025 to End Stigma and Discrimination against Persons Affected by Leprosy" was held in Bhubaneswar, Odisha, India. Read More 

 

REPORT
Global Appeal 2025 to End Stigma and Discrimination against Persons Affected by Leprosy launched from Odisha, India

In 2006, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa, with the support of The Nippon Foundation, launched the first Global Appeal to End Stigma and Discrimination against Persons Affected by Leprosy from Delhi, India. Read more

 

50th Anniversary of WHO–TNF/SHF Partnership
History preservation at Fontilles sanatorium saves a model of compassionate care

José Manuel Amorós Muñoz, Director General, Fontilles Foundation

In 1991, encouraged by the effectiveness of multidrug therapy (MDT), the World Health Assembly passed a resolution to eliminate leprosy as a public health problem by the year 2000. Read more 

 

VIEWPOINT
Too much fear of transmission, not enough awareness of invisible disabilities

As part of the Global Appeal 2025 to End Stigma and Discrimination against Persons Affected by Leprosy held in India on Jan. 30, the Leprosy Bulletin interviewed two persons affected by leprosy living in Odisha to learn about their experiences. Read more

 

AMBASSADOR'S JOURNAL

Goodwill Ambassador visits India and Sri Lanka for World Leprosy Day and Global Appeal 2025

On Jan. 29, 2025, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa left Japan for an 11-day visit to India and Sri Lanka. Read more

 

ANNOUNCEMENT
In remembrance of Fichrin Hidayat, a true fighter for persons affected by leprosy in Indonesia

Contributed by Hasan Basri, Sasakawa Leprosy Initiative Young Scholar

Fichrin was one of four participants in the Sasakawa Leprosy Initiative's Young Scholar Program in Indonesia, along with myself, Kasmawati, and Yusniati. Fichrin and I lived together in Makassar for three-and-a-half months, sharing accommodation, experiences, and stories. Read more 

 

BACK ISSUES 

 

We hope that you would enjoy reading the latest Leprosy Bulletin. 

 

Takahiro NANRI, Ph.D.
President, Sasakawa Health Foundation

*********************************************************
Sasakawa Leprosy (Hansen's Disease) Initiative
Sasakawa Health Foundation
Tel：81-3-6229-5377, Fax：81-33-6229-5388
email: hansen@shf.or.jp

*********************************************************

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/b4018fd1-4898-406d-966b-a4f242c680d4n%40googlegroups.com.
Posted by at No comments:

Sunday, March 16, 2025

Fw: Ref.: (LML) Maranhão, Brazil

 

 

Leprosy Mailing List –  March 16,  2025

 

Ref.:  (LML)  Maranhão, Brazil

From: Joel Almeida, Mumbai, India

 

 

 

Dear Pieter & colleagues,

Our Brazilian colleagues have long been at the forefront of many aspects of HD control and research. These include elucidating molecular biology in HD (leprosy), socio-economic determinants, social mobilisation, management information systems, clinical skills, diagnostic kits and approaches, GIS, solidarity with persons who experience(d) HD, conditional cash transfers, primary health care etc. 

Newly diagnosed LL (lepromatous) patients with deformity at (delayed) diagnosis are an important source of viable bacilli. So too are reinfected but unprotected LL patients who previously completed 12 monthly doses of MDT. COVID with reduced physical interactions might have been a blessing in disguise. It led to delayed detection of LL HD but also reduced transmission owing to physical distancing. Accordingly, we might well be at a turning point in the endemic. We can shut down sources of viable bacilli now. In that way we can turn any temporary reduction in transmission into a full-blown and permanent decline of the endemic.

Maranhão is not the richest Brazilian state. However, it seems to be on the verge of achieving rapid decline in the incidence rate of LL (lepromatous) HD. The number of newly detected HD cases dropped substantially from 2023 to 2024. The graphs below show only 2014 to 2023, not 2024. Notably, during 2021 to 2023 there is no increase in LL patients with deformity at diagnosis. This is promising. It indicates reduction in an important source of viable bacilli. 

 

 

 

Prolonging MDT, or other ways of shutting down reinfection of LL patients in Maranhão, is likely to ensure a sustained rapid decline of HD in Maranhão. 15% to 20% annual decline in the incidence rate of LL HD (and all HD) was achieved in  several projects in endemic areas, leading to near-zero incidence rate of new HD. This is all the more encouraging because at the time they were still on relatively low incomes per capita (e.g., Karigiri (India), Karonga (Malawi), Weifang/Shandon (China), Thailand. 


Maranhão has every possibility of succeeding just as those other endemic areas did. Time will tell. The signs are promising, given the steady reduction in new LL cases with deformity at diagnosis.

With all sincerity,

 

Joel Almeida

 

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/cf1c4526-8051-4fe5-9295-4c866e71d793n%40googlegroups.com.
Posted by at No comments:

Friday, March 7, 2025

Fw: Ref.: (LML) Infolep monthly overview of new publications on leprosy. March, 2025


 

Leprosy Mailing List –  March 7,  2025

 

Ref.:  (LML) Infolep monthly overview of new publications on leprosy. March, 2025

From: Roos Geutjes, Amsterdam, the Netherlands

 

 

Dear colleagues, 

We are pleased to announce that the ILEP ocular leprosy photo database has been successfully developed and integrated into the Infolep platform. As we prepare for its public launch, we are inviting ophthalmologists and other experts to contribute high-quality ocular leprosy photographs and metadata to help build a robust and comprehensive resource. Your contributions will be instrumental to populating the database and advancing training, research, integrated service delivery, and AI-based screening tools for ocular leprosy worldwide. Please find more information below on how to contribute to this initiative. 

Enjoy reading, and please let us know if we've missed anything or if you would like to share any resources through our platform.

Warm regards,

Roos Geutjes

www.infolep.org
info@infolep.org

Practical resources

Lecture On Leprosy (Hansen's Disease) Explained: Microbiology, Immunology & Clinical Aspects
Sinha S. 2025.

The Right to Health made workable for health professionals (Online course)
IFHHRO | Medical Human Rights Network . IFHHRO | Medical Human Rights Network. 2025.

Compassion and primary health care
Addiss D, Graham A, Richards A, et al. Word Health Organization. 2025.

Podcast: power and responsibility in global health
TDR: For research on diseases of poverty. 2025.

Massive Open Online Course (MOOC) on Embedding Social Innovation and Community Engagement in Implementation Research 
Special Ptrogramme for Research & Training in Tropical Diseases (TDR). 2025. 

Partner Capacity Strengthening (Online course)
INTRAC. 2025.

Advocacy Strategy And Influencing Skills (Online course)
INTRAC. 2025.

Monitoring, Evaluation, and Learning (Online course)
INTRAC. 2025.

ILEP Ocular Leprosy Database

We are pleased to announce that the ILEP ocular leprosy photo database has been successfully developed and integrated into the Infolep platform. As we prepare for its public launch, we are inviting ophthalmologists and other experts to contribute high-quality ocular leprosy photographs and metadata to help build a robust and comprehensive resource. Your contributions will be instrumental to populating the database and advancing training, research, integrated service delivery, and AI-based screening tools for ocular leprosy worldwide. 

Submission Guidelines
By clicking here, you will find a Guidance Document including:

  1. An overview of the ILEP Ocular Leprosy Photo Database and its objectives.
  2. The list of ocular leprosy conditions included in the database.
  3. The naming convention for photos and metadata forms.
  4. Detailed instructions on how to submit photographs and metadata.
  5. Basic guidelines for taking ocular photographs.

How to submit
Please follow the attached instructions to upload your photographs and metadata. You are welcome to submit multiple high-quality photographs. Note that each photo should be accompanied by its metadata form. In case of any technical difficulties or questions, please contact Monty Mukhier, who would be happy to assist.
Thank you in advance for your contributions to the database. They will play a crucial role in improving awareness and prevention of ocular complications in leprosy.
We greatly appreciate your time, effort, and expertise in making this initiative a success.

Best regards,
The ILEP Ocular Leproy Database Team

Other new publications

Feel free to contact us to receive full-text versions if these cannot be found through the Infolep portal.

Disability inclusion or exclusion? Insights from rural community-based rehabilitation stakeholders
Chen N, Qi C. Informa UK Limited. Disability &amp; Society. 2025.

Plasma irisin levels in newly diagnosed leprosy patients: a case-control study
Ali M, El Taieb M, Younis A, et al. Archives of Dermatological Research. 2025.

Health-related quality of life implications of plantar ulcers resulting from neuropathic damage caused by leprosy: An analysis from the trial of autologous blood products (TABLE trial) in NepalGibbs NK, Ochalek J, Napit IB, et al. Public Library of Science (PLoS). PLOS ONE. 2025.

Fluorescent Microscopy: A Useful and Adjunct Tool in Leprosy Diagnosis: A Cross Sectional StudyJain SA, Walke VA, Asati D, et al. Farname, Inc.. Iranian Journal of Pathology. 2025; 20 (1) : 8.

A Multicenter evaluation of leprosy rapid test Fast ML Flow Hanseníase in BrazilSaavedra DP, Nobre ML, Guimarães RA, et al. Springer Science and Business Media LLC. European Journal of Clinical Microbiology & Infectious Diseases. 2025.

Insights into leprosy epidemiology from an isolated population located in the Brazilian Amazon
de Oliveira Mackert CC, Lázaro FP, Olandowski M, et al. Springer Science and Business Media LLC. Scientific Reports. 2025.

Risk factors for disabilities among leprosy patients: A systematic review
Kurane S, Dani P. South Eastern European Journal of Public Health. 2025.

A socio-ecological model of the management of leprosy reactions in Indonesia and India using the experiences of affected individuals, family members and healthcare providers
Putri AI, Peters RMH, de Sabbata K, et al. Springer Science and Business Media LLC. BMC Health Services Research. 2025.

Exploring the Neurological Manifestations of Leprosy: Clinical Insights and Implications
Rashidi M, Pitton Rissardo J, Byroju VV, et al. Springer Science and Business Media LLC. Cureus. 2025.

Molecular Detection of Mycobacterium leprae and the Process of Infection and Illness in Contacts of Leprosy Patients: A Systematic ReviewVidal SL, Batista LCF, Lages DDS, et al. MDPI AG. Tropical Medicine and Infectious Disease. 2025; 10 (2) : 14. 

Efeitos adversos no tratamento da hanseníase: uma revisão sistemática
Espanhol HA, Hamada JPCB, Antonio GLN, et al. Brazilian Journals. Brazilian Journal of Health Review. 2025; 8 (1) : 14. 

Terapêuticas de enfermagem para pessoas com limitações decorrentes da hanseníase
Manda AM, Fernandes MA, Costa RMPG. Revista Eletronica Acervo Saude. Revista Eletrônica Acervo Saúde. 2025.

Advancing health equity: Why guideline development must prioritize fairness and justice
Dewidar O, Pardo JP, Peña‐Rosas JP, et al. Wiley. Clinical and Public Health Guidelines. 2025.
 

Occurrence of leprosy among patients with cutaneous leishmaniasis in a hyperendemic area for both diseases
de Carvalho DA, Luz PJGG, da Mata MLKS, et al. Elsevier BV. International Journal of Infectious Diseases. 2025.

Estudo de casos novos de hanseníase no ano de 2022 em três municípios hiperendêmicos do MaranhãoAlves R, Carvalho G, Lima A. Estrabao. Estrabão. 2025. 

Belonging and pride in people with disabilities: An approach to counteract stigma.
Qin S, Isadore K, Chun J, et al. American Psychological Association (APA). Stigma and Health. 2025.

Harnessing digital health to achieve equitable and efficient health systems
Tangcharoensathien V, Labrique A, Rapeepong Suphanchaimat DL, et al. WHO Press. Bulletin of the World Health Organization. 2025; 103 (2) : 2. 

Understanding experiences of neglected tropical diseases of the skin: a mixed-methods study to inform intervention development in EthiopiaKaba M, Hailemichael Y, Alemu AY, et al. BMJ. BMJ Global Health. 2025; 10 (2) : 12. 

Health workers' adoption of digital health technology in low- and middle-income countries: a systematic review and meta-analysis
Wang M, Huang K, Li X, et al. WHO Press. Bulletin of the World Health Organization. 2025; 103 (2) : 16. 

Human Rights and Leprosy: A Bibliometric Analysis
Thahir PS, Agustina DL, Tofly H. Atlantis Press SARL. Advances in Social Science, Education and Humanities Research. 2025.

Development and validation of a machine learning approach for screening new leprosy cases based on the leprosy suspicion questionnaire
Mendonça Ramos Simões M, Rocha Lima F, Barbosa Lugão H, et al. Springer Science and Business Media LLC. Scientific Reports. 2025.

Challenges associated with dapsone for leprosy treatment in Indonesia - urgent need for access to alternative antimicrobial drugs
Krismawati H, Harianja M, Oktavian A, et al. Elsevier BV. The Lancet Regional Health - Southeast Asia. 2025. 

Urine-based ELISA using a recombinant chimeric protein for the diagnosis of paucibacillary and multibacillary leprosy
Câmara RS, Pereira IA, Espíndola GC, et al. Elsevier BV. Tuberculosis. 2025.

Neglected tropical diseases in Yemen: a systematic review of epidemiology and public health challenges
Alhothily IAA, Dapari R, Dom NC. Springer Science and Business Media LLC. BMC Public Health. 2025.

Força de preensão palmar e grau de participação social em pacientes de hanseníase
Ferreira SSP, Martins KKS, Rolim CMS, et al. Brazilian Journals. Caderno Pedagógico. 2025; 22 (2) : 16.

Insight into Paediatric Versus Adult Leprosy: A Comparative, Analytical Study from India
Pandhi D, Gupta P, Singal A, et al. Ovid Technologies (Wolters Kluwer Health). Indian Journal of Dermatology. 2025. 
 

Case Reports


A Case Report on the association Between Leprosy, Type 2 Diabetes Mellitus, and Peripheral Neuropathy causing Diabetic Foot Ulcer
Suhail Z, Askari S. Journal of Pakistan Endocrine Society. 2024.  

Type II Lepra Reaction With Idiopathic Intracranial Hypertension: A Case Report With Challenges in Diagnosis and Management
Zhu R, Jiang Y, Zhan Y, et al. Ovid Technologies (Wolters Kluwer Health). International Journal of Dermatology and Venereology. 2025.  

Anetoderma as a Cutaneous Manifestation of Leprosy: A Report of Two Cases
Palaniappan V, Pavithren T, Youvalakshmi S, et al. Ovid Technologies (Wolters Kluwer Health). Indian Dermatology Online Journal. 2025.  

Erythema nodosum as the initial presentation of leprosy in a 15-year-old boy: a case report on Ethiopia's persistent elimination challenges
Tukeni KN, Aga TM, Abadiko EA, et al. Frontiers Media SA. Frontiers in Medicine. 2025. 

Misdiagnosis of Leprosy with Severe Reversal Reaction as Psoriatic Arthritis: A Case Report and Literature Review
Gunawan H, Hidayah R, Ruchiatan K, et al. Informa UK Limited. Clinical, Cosmetic and Investigational Dermatology. 2025.

Necrotic erythema nodosum leprosum – A case of severe lepromatous reaction in a multibacillary leprosy patient
Nagarajan HDP, Kamaraj B, Selvanathan K, et al. Elsevier BV. IDCases. 2025. 

Lucio phenomenon: a case report on an overlooked reaction in lepromatous leprosy
Sajjachareonpong N, Sudtikoonaseth P, Kampirapap K, et al. PAGEPress Publications. Dermatology Reports. 2025. 

Miiase nasal em paciente com diagnostico de Hanseniase atendido no serviço de otorrinolaringologia da Fundação Hospital Adriano Jorge: um relato de caso|
Guimarães ACPDA, Ferreira FDS, Dantas JM, et al. Brazilian Journals. Brazilian Journal of Health Review. 2025; 8 (1) : 10.  

Rare Masqueraders of Pure Neuritic Leprosy: A Report of Four Cases
Sadhukhan S, Bhardwaj A, Kumar S, et al. Ovid Technologies (Wolters Kluwer Health). Indian Dermatology Online Journal. 2025; 16 (2) : 6. 

News & Events


Call for Funding (Global Health Innovative Technology Fund)

Second global meeting on skin-related neglected tropical diseases (skin NTDs) 
March 24-26, 2025; hybrid; Geneva, Switzerland.

Conference on Neglected Tropical Diseases 2025
May 16, 2025. Windhoek, Namibia.

European Congress for Tropical Medicine and International Health 2025
September 29-October 2, 2025, Hamburg
Save the Date! ECTMIH 2025 is currently still in the planning stage. All information is expected to be available from January 2025 and registration will be possible from then on.

16th Annual NNN Conference 2025
Save the date for the 16th Annual NNN Conference 2025, which will take place in Kampala, Uganda, from September 30 to October 2. Further details will be shared soon.

Tailored guidelines and reduced stigma needed to tackle leprosy, Irish case study reveals
Stewart L.

Funding Opportunity: Host a World Skin Day 2025 Event
Members, supporters, and partners are invited to apply for funding to host a local or regional event for World Skin Health Day (WSHD) 2025. Applications are open until 15 March 2025.

 

Global Disability Summit 2025 
April 2-4, 2025; Berlin, Germany. 
The Global Disability Summit aims to galvanize global efforts to realize disability inclusion around the world. It is a mechanism bringing together a wide variety of high-level stakeholders, engaging and discussing the progress in disability inclusion: governments, multilateral agencies, the private sector, academia and civil society organizations, organizations of persons with disabilities, and foundations. Registration is open.

The Twelfth EDCTP Forum
June 15-20, 2025; Kigali Convention Centre, Kigali, Rwanda
The theme for the 2025 Forum is "Better health through global research partnerships". Registration is open.

3rd Global Forum of People's Organizations on Hansen's Diseas
ILEP member Sasakawa Health Foundation, in consultation with persons affected by leprosy and other stakeholders, is organizing the 3rd Global Forum of People's Organizations. This will be held in Bali, Indonesia from 4-6 July.

22nd International Leprosy Congress 
July 5-9, 2025; Bali Nusa Dua Convention Centra (BNDCC), Bali, Indonesia 
This year the 22nd International Leprosy Congress (ILC) will be held in Bali, Indonesia! The congress uphold the theme: "Towards a World with Zero Leprosy". The theme aims to enhance the evidence into the clinical care in leprosy early diagnosis and therapeutics in the global era and prepare to face the new perspective of dermatology practice. The deadline of abstract submission is 28th of February and the deadline for late registration is July the 6th.

Links

Info Hansen - A innovative hub for knowledge sharing about Hansen's Disease
 

ALLF - Official website of the Association des Léprologues de Langue Française
 

LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in leprosy to share ideas, information, experiences and questions
 

InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)

ILEP newsletter archive

GPZL newsletter subscription

WHO Goodwill Ambassador's Leprosy Bulletin

Leprosy Review

Leprosy Review Repository (1928-2001)

Fontilles Revista de Leprología

Indian Journal of Leprosy

Hansenologia Internationalis

HARP - database of Hansen's Disease Antimicrobial Resistance Profiles

GDPR & the Infolep newsletter

 
New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our privacy statement and mailing list.

Infolep sends out monthly e-mails with an overview of recent publications on leprosy and related issues. The purpose of this activity is to keep subscribers up to date.

Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can update your preferences or unsubscribe from this list at any time.

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/bc7decb8-b4fa-4b88-b74b-8c518d77c1acn%40googlegroups.com.
Posted by at No comments:
Subscribe to: Posts (Atom)